Mobic (meloxicam) is a nonsteroidal anti-inflammatory drug (NSAID) which is often part of the pain management treatment plan, and provides a non-opioid alternative. Per the Official Disability Guidelines, it is recommended at the lowest dose for the shortest duration. They also carry a black box warning for adverse cardiovascular and gastrointestinal events. Importantly, meloxicam is contraindicated in the setting of coronary artery bypass graft surgery.
The table outlines a significant difference in the lowest average wholesale price (AWP) between the previous and current AWP, per CMS’ recognized and approved compendium, Red Book. Updates to the MSA will significantly mitigate Part D allocation and save Workers’ Compensation payers money.
Current Pricing Spectrum and Savings
|Meloxicam Strength||Previous Lowest AWP||Current Lowest AWP||~ % Savings|
ExamWorks Clinical Solutions’ Doctors of Pharmacy offer risk evaluation mitigation, alternatives to high cost Medicare-covered medications, and clarification of drug regimens to provide the most accurate and defensible MSA. The goal of the program is to impact medication therapy and mitigate MSA drug costs by consulting with the treating provider on the clinical rationale. ExamWorks utilizes technology and compendia databases which are recognized and supported by the CMS to support inclusion or exclusion of a drug under the Part D benefit. We will continue to monitor changes in medication pricing as well as availability of generic equivalents within the marketplace.
For questions about medications or the ExamWorks Clinical Solutions Pharmacy programs, please contact Nahla D. Rizkallah, PharmD at 678.256.5086 or email@example.com